Time trend and risk factors of avascular bone necrosis in patients with systemic lupus erythematosus

Abstract

Objectives

The objective of this paper is to study the time trend and risk factors of avascular bone necrosis (AVN) in patients with systemic lupus erythematosus (SLE).

Methods

Between 1999 and 2014, patients who fulfilled the ACR criteria for SLE and developed symptomatic AVN were identified from our cohort database and compared with those without AVN, matched for age, sex and SLE duration. The standardized incidence ratios (SIRs) of AVN in different SLE age groups were calculated from data derived from our hospital registry and population census. Risk factors for AVN were studied by logistic regression, adjusted by a propensity score for ever use of high-dose glucocorticoids (GCs).

Results

Fifty-five SLE patients with AVN and 220 SLE patients without AVN were studied. There were 104 AVN sites involved, with the hips being most commonly affected (82%). The point prevalence of AVN in our SLE cohort was 7.4%. The SIRs of AVN in our SLE patients were 131 (86.6–199; p < 0.001) and 56.0 (34.3–91.4; p < 0.001), respectively, in the periods 1995–2004 and 2005–2014. In both decades, the age-stratified SIR was highest in the youngest age group (<19 years). AVN patients were more likely to be treated with GCs and had received a significantly higher cumulative dose of prednisolone since SLE diagnosis (16.5 vs 10.7 grams; p = 0.001). The SLE damage score (excluding AVN) was also significantly higher in AVN than non-AVN patients (2.5 vs 0.4; p < 0.001). Logistic regression revealed that preceding septic arthritis of the involved joint (odds ratio (OR) 17.7 (1.5–205); p = 0.02), cushingoid body habitus (OR 2.4 (1.1–5.2); p = 0.04), LDL cholesterol level (OR 1.4 (1.0–1.9); p = 0.04), maximum daily dose of prednisolone (OR 6.4 (1.2–33.3); p = 0.03) and cumulative dose of prednisolone received in the first six months of the first lupus flare (OR 1.3 (1.0–1.8); p = 0.046) were independently associated with AVN.

Conclusions

AVN is prevalent in SLE, particularly in younger patients. The use of GCs remains the strongest independent risk factor. A trend of reduction in the SIR of AVN in our SLE patients is observed over the past two decades.

Keywords

Standardized incidence ratio avascular necrosis lupus damage

Get full access to this article

View all access options for this article.

References

Zizic

. Osteonecrosis. Curr Opin Rheumatol 1991; 3: 481–489.

Assouline-Dayan

Chang

Greenspan

Shoenfeld

Gershwin

. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002; 32: 94–124.

Dubois

Cozen

. Avascular (aseptic) bone necrosis associated with systemic lupus erythematosus. JAMA 1960; 174: 966–971.

Mok

Lau

Wong

. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 1998; 37: 895–900.

Petri

. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins lupus cohort: An update. Arthritis Care Res 1995; 8: 137–145.

Kunyakham

Foocharoen

Mahakkanukrauh

Suwannaroj

Nanagara

. Prevalence and risk factor for symptomatic avascular necrosis development in Thai systemic lupus erythematosus patients. Asian Pac J Allergy Immunol 2012; 30: 152–157.

Zizic

Marcoux

Hungerford

Dansereau

Stevens

. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 1985; 79: 596–604.

Uea-areewongsa

Chaiamnuay

Narongroeknawin

Asavatanabodee

. Factors associated with osteonecrosis in Thai lupus patients: A case control study. J Clin Rheumatol 2009; 15: 345–349.

Shigemura

Nakamura

Kishida

. Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: Prospective MRI study. Rheumatology 2011; 50: 2023–2028.

10.

Sayarlioglu

Yuzbasioglu

Inanc

. Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int 2012; 32: 177–182.

11.

Oinuma

Harada

Nawata

. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001; 60: 1145–1148.

12.

Nakamura

Harada

Oinuma

Iida

Kishida

Takahashi

. Spontaneous repair of asymptomatic osteonecrosis associated with corticosteroid therapy in systemic lupus erythematosus: 10-Year minimum follow-up with MRI. Lupus 2010; 19: 1307–1314.

13.

Watanabe

Tsuchida

Kanda

Tamaki

. Avascular necrosis of bone in systemic lupus erythematosus. Scand J Rheumatol 1997; 26: 184–187.

14.

Prasad

Ibañez

Gladman

Urowitz

. The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: A nested case-control study of inception patients. Lupus 2007; 16: 157–162.

15.

Joo

Sung

Shim

. Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: A nationwide epidemiologic study. Rheumatol Int 2015; 35: 879–886.

16.

Nagasawa

Ishii

Mayumi

. Avascular necrosis of bone in systemic lupus erythematosus: Possible role of haemostatic abnormalities. Ann Rheum Dis 1988; 48: 672–676.

17.

Mont

Glueck

Pacheco

Wang

Hungerford

Petri

. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 1997; 24: 654–662.

18.

Velayos

Lordholt

Smyth

Priest

. Arthroplasty associated with steroid therapy. Ann Intern Med 1966; 64: 759–771.

19.

Ono

Tohjima

Komazawa

. Risk factors of avascular necrosis of the femoral head in patients with systemic lupus erythematosus under high-dose corticosteroid therapy. Clin Orthop Relat Res 1992; 277: 89–97.

20.

Migliaresi

Picillo

Ambrosone

. Avascular osteonecrosis in patients with SLE: Relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 1994; 3: 37–41.

21.

Gladman

Urowitz

Chaudhry-Ahluwalia

Hallet

Cook

. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 761–765.

22.

Calvo-Alén

McGwin

Toloza

Fernandes

. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: Results of a nested matched case-control study. Ann Rheum Dis 2006; 65: 785–790.

23.

Jaovisidha

Denprechawong

Suwannalai

Janwityanujit

. Asymptomatic avascular osteonecrosis of the hip in new patients diagnosed as systemic lupus erythematosus in Ramathibodi Hospital. J Med Assoc Thai 2007; 90: 1382–1390.

24.

Vakil

Sparberg

. Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology 1989; 96: 62–67.

25.

Hedri

Cherif

Zouaghi

. Avascular osteonecrosis after renal transplantation. Transplant Proc 2007; 39: 1036–1038.

26.

Powell

Chang

Naguwa

Cheema

Gershwin

. Steroid induced osteonecrosis: An analysis of steroid dosing risk. Autoimmun Rev 2010; 9: 721–743.

27.

Mok

. Update on emerging drug therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs 2010; 15: 53–70.

28.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

29.

Petri

Kim

Kalunian

. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–2558.

30.

Gladman

Chaudhry-Ahluwalia

Ibañez

Bogoch

Urowitz

. Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 2226–2229.

31.

Petri

Bechtel

Dennis

. Burden of corticosteroid use in patients with systemic lupus erythematosus: Results from a Delphi panel. Lupus 2014; 23: 1006–1013.

32.

Zhu

Pan

. The risk factors of avascular necrosis in patients with systemic lupus erythematosus: A meta-analysis. Inflammation 2014; 37: 1852–1864.

33.

Vande Berg

Malghem

Lecouvet

Devogelaer

Maldague

Houssiau

. Fat conversion of femoral marrow in glucocorticoid-treated patients. A cross-sectional and longitudinal study with magnetic resonance imaging. Arthritis Rheum 1999; 42: 1405–1411.

34.

Jones

Jr . Fat embolism and osteonecrosis. Orthop Clin North Am 1985; 16: 595–633.

35.

Huscher

Thiele

Gromnica-Ihle

. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68: 1119–1124.

36.

Vidigal

Jr Vidigal

Fernandes

. Avascular necrosis as a complication of septic arthritis of the hip in children. Int Orthop 1997; 21: 389–392.

37.

Galindo

Mateo

Pablos

. Multiple avascular necrosis of bone and polyarticular septic arthritis in patients with systemic lupus erythematosus. Rheumatol Int 2005; 25: 72–76.

38.

Sekiya

Yamaji

Yang

Tsuda

Takasaki

. Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus. Rheumatol Int 2010; 30: 1587–1593.